The findings of Gager et al. [27] concluded that SGLT2 inhibitors play a significant role in decreasing the risk of cardiovascular diseases, particularly in patients with heart failure (HF) [45]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.